VistaGen Therapeutics (VTGN) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Join SI Premium – FREE
VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).
For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- RCM Technologies (RCMT) Tops Q2 EPS by 17c
- Eos Energy Enterprises (EOSE) PT Lowered to $5 at B.Riley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
